Komori
Governance4886ASKA Pharmaceutical Holdings Co.,Ltd.Pharmaceuticals

Notice Regarding the Board of Directors’ Opinion on the Shareholder Proposal

The Board of Directors resolved to oppose the shareholder proposal to elect 2 outside directors. The Company has determined that the candidates proposed by the shareholder are unsuitable due to concerns regarding their independence and conflicts of interest.

Worth reading
56In focus
Scored from 2 of 5 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
2
People
Wording
Conditional
How definitive the wording is.

Governance structure

The Company plans to transition to a company with an Audit and Supervisory Committee, subject to approval at the General Meeting of Shareholders.
Controlling shareholder
Dalton and others hold 21.6% of the Company’s voting rights, or at least 20%. Whether they are explicitly identified as a controlling shareholder is Not disclosed21.60%Voting rights

When one company holds most of the voting rights, its wishes are more likely to prevail in management. How the interests of minority shareholders are protected is a key issue.

Committee1
Group Nomination Committee: all 3 members are independent outside directors
Percentage of outside members 100% outside members
Takeover defenses

Implemented (a policy regarding responses to large-scale purchase actions and similar activities, introduced on 1 July 2025). Whether it will be renewed or abolished is Not disclosed

Pre-agreed countermeasures in preparation for an unsolicited takeover attempt.

Changes this time

Subject to approval at the General Meeting of Shareholders, the Company plans to transition to a company with an Audit and Supervisory Committee. It has also decided to adopt a policy under which outside directors will comprise a majority of the Board of Directors. As a Company proposal, James Feliciano is scheduled to be submitted as a candidate for outside director.

Governance structure
ItemDetails
Corporate Governance StructureThe Company plans to transition to a company with an Audit and Supervisory Committee, subject to approval at the General Meeting of Shareholders.
CommitteeGroup Nomination Committee: all 3 members are independent outside directors (100% outside members)
Takeover defensesImplemented (a policy regarding responses to large-scale purchase actions and similar activities, introduced on 1 July 2025). Whether it will be renewed or abolished is Not disclosed
Controlling shareholderDalton and others hold 21.6% of the Company’s voting rights, or at least 20%. Whether they are explicitly identified as a controlling shareholder is Not disclosed
Changes this timeSubject to approval at the General Meeting of Shareholders, the Company plans to transition to a company with an Audit and Supervisory Committee. It has also decided to adopt a policy under which outside directors will comprise a majority of the Board of Directors. As a Company proposal, James Feliciano is scheduled to be submitted as a candidate for outside director.
Items this document does not state (3)
Number of directorsNumber of independent officersPolicy on cross-shareholdings

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The candidates proposed by the shareholder do not meet the Company’s independence standards, and there are concerns that they could steer the Company toward going private through an MBO or similar transaction as representatives of the interests of Dalton and others, potentially creating conflicts of interest with general shareholders and adversely affecting the independence and governance of the Board of Directors.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Board of Directors’ Opinion on the Shareholder Proposal | ASKA Pharmaceutical Holdings Co.,Ltd. (4886) timely disclosure | Komori